NFCS Phase 2 & 3 findings
Phase 2 Covid NFCS Performance Summary Report
Policy Briefing
NFCS Scheme Performance
During Phase 2 (March 2023 to February 2024) we investigated the performance of a number of NFCS. We sought information from all of the multinational NFCS (coverage shown in blue) and from the national NFCS (shown in red).
We sent out online surveys looking at:-
| Who made the claims? | Was it the vaccine injured individual? A representative? A lawyer? We asked a number of demographic questions including:- claimant age, gender, ethnicity, healthcare professional status |
| How claims were processed? | How many claims were accepted? How many rejected? How many carried forward? What was the average claim processing time? |
| Value of Awards? | The average, maximum and minimum award values, indicating the range of values |
| Appeals | How many appeals were made? How many were successful? |
We also asked about how potential claimants could find information out about the NFCS.
We are very grateful to the NFCS that did respond to our survey, despite extensive follow up, it was a lower proportion than we would have liked.
The Performance Summary Report details our findings.
Policy Recommendations
During Phase 3 we undertook a literature search on NFCS and sent out detailed qualitative surveys to claimants in Canada, Estonia, Finland, New Zealand and the UK. We also carried out a literature review in Japan, Poland, and Hungary (Hungary has a vaccine NFCS, but did not include covid vaccines), and we intended to send out surveys. However, we encountered difficulties in distributing surveys in Japan, Poland and Hungary as we could not identify appropriate vaccine injured support groups to channel the surveys through.
The outputs from phase 3 are national reports, which will be added when completed and a Policy Briefing.